

08-09-2002



102184945

TRADEMARKS ONLY

DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Form PTO-1594 (Rev. 03/01) OMB No. 0651-0027 (exp. 5/31/2002)

Tab settings ⇨ ⇨ ⇨

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):  
 MedcoHealth Solutions, Inc.  
*F-2-02*

Individual(s)       Association  
 General Partnership       Limited Partnership  
 Corporation-State - Delaware  
 Other \_\_\_\_\_

Additional name(s) of conveying party(ies) attached?  Yes  No

2. Name and address of receiving party(ies)  
 Name: Medco Health Solutions, Inc.  
 Internal  
 Address: \_\_\_\_\_  
 Street Address: 100 Parsons Pond Drive  
Franklin Lakes, New Jersey 07417  
 City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Individual(s) citizenship \_\_\_\_\_  
 Association \_\_\_\_\_  
 General Partnership \_\_\_\_\_  
 Limited Partnership \_\_\_\_\_  
 Corporation-State Delaware  
 Other \_\_\_\_\_

If assignee is not domiciled in the United States, a domestic representative designation is attached:  Yes  No  
 (Designations must be a separate document from assignment)  
 Additional name(s) & address(es) attached?  Yes  No

3. Nature of conveyance:  
 Assignment       Merger  
 Security Agreement       Change of Name  
 Other Amended and Re-Styled Certificate of Incorporation  
 Execution Date: June 6, 2002

4. Application number(s) or registration number(s):  
 A. Trademark Application No.(s)  
76/349176  
 Additional number(s) attached  Yes  No

B. Trademark Registration No.(s)  
2,522,423  
 Additional number(s) attached  Yes  No

5. Name and address of party to whom correspondence concerning document should be mailed:  
 Name: Susan C. Mattson  
 Internal Address: WS3B-07  
Merck & Co., Inc.  
 Street Address: One Merck Drive  
P. O. Box 100  
Whitehouse Station, New Jersey 08889-0100  
 City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

6. Total number of applications and registrations involved: 41

7. Total fee (37 CFR 3.41).....\$1,040.00  
 Enclosed  
 Authorized to be charged to deposit account

8. Deposit account number: 13-2752  
 (Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.  
*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*

Susan C. Mattson      *Susan C. Mattson*      August 1, 2002  
 Name of Person Signing      Signature      Date

Total number of pages including cover sheet, attachments, and document: 19

08/08/2002 LNUELLER 00000191 132752 76349176  
 01 FC:481      40.00 CH  
 02 FC:482      1000.00 CH

Mail documents to be recorded with required cover sheet information to:  
 Commissioner of Patent & Trademarks, Box Assignments  
 Washington, D.C. 20231

Trademark	Application Number
GENERIC FIRST	76349176
GENERIC FIRST	76050964
LIVE LIFE WELL	76119975
LIVE LIFE WELL	76119724
LIVE LIFE WELL	76119723
LIVE LIFE WELL	76119976
MMRXCONSULTANT.COM	76324954
RULESTATION	76142822
SMART CHOICE	76401425
THE ESSENTIAL MEDICATION GUIDEBOOK TO HEALTHY AGING	76379019
YOU NEED A HARDER WORKING DRUG PLAN	76279413

**Trademark Registrations**

<b>Trademark</b>	<b>Reg. Number</b>
EXPERXT	2522423
FLEX RX - FLEXIBILITY IN A MAINTENANCE PRESCRIPTION DRUG PROGRAM	1522893
FLEXRX	2030570
HEART FACTS	2296609
INFORMED PRESCRIBER	2453142
M and Design	1476148
MAKING SENSE	2375635
MEDICATION GUIDEBOOK FOR HEALTHY AGING	2551345
MILESTONES	2176828
Miscellaneous Design - Rx Character	2350073
NRx (Stylized)	1436039
OPTIMAL DIABETES CARE	2312219
OPTIMAL HEALTH	2449414
PARTNERS FOR HEALTHY AGING	2175231
PARTNERS FOR HEALTHY AGING	2175230
PERxSPECTIVES	2504945
POSITIVE APPROACHES	2533722
POSITIVE APPROACHES	2533721
PREFERRED PRESCRIPTIONS	1895760
QRX	2488747
RAISING AWARENESS	2347885
RAISING AWARENESS THROUGH EDUCATION	2352542
RxTODAY	2350913
SMART STEPS TO STRONG BONES	2296743
STOP AND THINK SAM and Design	2563249
STOP AND THINK SAM and Design	2563250
TIMED RELEASE	2151015
TRANSITIONS TO BETTER HEALTH	2304570
WELL INFORMED	2201651
YOURX PLAN	2444243

# Delaware

PAGE 1

*The First State*

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED ARE TRUE AND CORRECT COPIES OF ALL DOCUMENTS ON FILE OF "MEDCO HEALTH SOLUTIONS, INC." AS RECEIVED AND FILED IN THIS OFFICE.

THE FOLLOWING DOCUMENTS HAVE BEEN CERTIFIED:


CERTIFICATE OF FORMATION, FILED THE TWENTY-SIXTH DAY OF AUGUST, A.D. 1996, AT 10 O'CLOCK A.M.

CERTIFICATE OF MERGER, CHANGING ITS NAME FROM "MERGERCO DELAWARE NO. 1, L.L.C." TO "MERCK-MEDCO MANAGED CARE, L.L.C.", FILED THE TWENTY-SEVENTH DAY OF DECEMBER, A.D. 1996, AT 4 O'CLOCK P.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF MERGER IS THE THIRTY-FIRST DAY OF DECEMBER, A.D. 1996.

CERTIFICATE OF MERGER, FILED THE TWENTY-NINTH DAY OF JANUARY, A.D. 1997, AT 10 O'CLOCK A.M.

CERTIFICATE OF CONVERSION, CHANGING ITS NAME FROM "MERCK-MEDCO MANAGED CARE, L.L.C." TO "MEDCOHEALTH SOLUTIONS, INC.", FILED THE TWENTY-FIRST DAY OF MAY, A.D. 2002, AT 1:31 O'CLOCK P.M.



*Harriet Smith Windsor*  
Harriet Smith Windsor, Secretary of State

2656692 8100H

020473998

AUTHENTICATION: 1901617

DATE: 07-25-02

TRADEMARK

REEL: 002558 FRAME: 0537

# Delaware

*The First State*


PAGE 2

CERTIFICATE OF CORRECTION, FILED THE THIRTY-FIRST DAY OF  
MAY, A.D. 2002, AT 1 O'CLOCK P.M.

RESTATED CERTIFICATE, CHANGING ITS NAME FROM "MEDCOHEALTH  
SOLUTIONS, INC." TO "MEDCO HEALTH SOLUTIONS, INC.", FILED THE  
SEVENTH DAY OF JUNE, A.D. 2002, AT 12:30 O'CLOCK P.M.

CERTIFICATE OF CORRECTION, FILED THE THIRD DAY OF JULY, A.D.  
2002, AT 10:30 O'CLOCK A.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE AFORESAID  
CERTIFICATES ARE THE ONLY CERTIFICATES ON RECORD OF THE  
AFORESAID CORPORATION.



*Harriet Smith Windsor*  
Harriet Smith Windsor, Secretary of State

2656692 8100H

020473998

AUTHENTICATION: 1901617

DATE: TRADEMARK  
REEL: 002558 FRAME: 0538

**CORRECTED CERTIFICATE  
OF  
AMENDED AND RESTATED  
CERTIFICATE OF INCORPORATION  
OF  
MEDCO HEALTH SOLUTIONS, INC.**

I, the undersigned Senior Vice President, General Counsel and Secretary of Medco Health Solutions, Inc., a corporation organized and existing under, and by virtue of, the General Corporation Law of the State of Delaware, hereby certify as follows:

1. The amended and restated certificate of incorporation of the Corporation filed with the Secretary of State of the State of Delaware on June 7, 2002 incorrectly stated that the original certificate of incorporation was filed with the Secretary of State of the State of Delaware on August 26, 2002. The original certificate of formation was filed under the name Mergerco Delaware No. 1, L.L.C. on August 26, 1996. In connection with the corporation's conversion to a corporation, on May 21, 2002, a certificate of incorporation was filed with the Secretary of State of the State of Delaware.

2. The text of the amended and restated certificate of incorporation of the corporation is hereby corrected to read in its entirety as set forth on Exhibit A:

ffny03\richtph\461223.2

IN WITNESS WHEREOF, Medco Health Solutions, Inc. has caused this Corrected Certificate of Amended and Restated Certificate of Incorporation to be duly executed by an authorized officer of Medco Health Solutions, Inc. as of this 2nd day of July, 2002.

MEDCO HEALTH SOLUTIONS, INC.

By: /s/ David S. Machlowitz

Name: David S. Machlowitz

Title: Senior Vice President, General Counsel  
and Secretary

Exhibit A

**AMENDED AND RESTATED  
CERTIFICATE OF INCORPORATION  
OF**

**MEDCOHEALTH SOLUTIONS, INC.**

(to be Medco Health Solutions, Inc. upon filing)

I, the undersigned Senior Vice President, General Counsel and Secretary of MedcoHealth Solutions, Inc., a corporation organized and existing under, and by virtue of, the General Corporation Law of the State of Delaware, hereby certify as follows:

3. The original certificate of formation was filed under the name Mergerco Delaware No. 1, L.L.C. on August 26, 1996. In connection with the corporation's conversion to a corporation, on May 21, 2002, a certificate of incorporation was filed with the Secretary of State of the State of Delaware.

4. In accordance with Sections 242 and 245 of the General Corporation Law of the State of Delaware (the "DGCL"), this amended and restated certificate of incorporation has been (a) duly proposed by resolutions adopted and declared advisable by the board of directors of the corporation acting by written consent in accordance with Section 141(f) of the DGCL, (b) approved by written consent of the holder of all of the outstanding shares of capital stock of the corporation in accordance with Section 228 of the DGCL and (c) duly executed by an officer of the corporation in accordance with Section 103 of the DGCL and, upon filing with the Secretary of State in accordance with Section 103, shall supersede the original certificate of incorporation, as amended and restated, and shall, as it may thereafter be amended in accordance with its terms and applicable law, be the certificate of incorporation of the corporation.

5. Pursuant to Section 103(d) of the DGCL, this amended and restated certificate of incorporation shall become effective upon filing with the Secretary of State of the State of Delaware.

6. The text of the certificate of incorporation of the corporation is hereby amended and restated to read in its entirety as follows:

FIRST. The name of the corporation is: Medco Health Solutions, Inc.

SECOND. The address of the corporation's registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street in the City of Wilmington, County of New Castle, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company.

THIRD. The purpose of the corporation is to engage in any lawful act or activity for which corporations may be organized under the DGCL.



FOURTH. The total number of shares of all classes of stock which the corporation shall have authority to issue is 1,010,000,000 of which 1,000,000,000 shares with the par value of \$0.01 per share shall constitute a class designated as Common Stock and 10,000,000 shares with the par value of \$0.01 per share shall constitute a class designated as Preferred Stock. Shares of Preferred Stock may be issued in one or more series from time to time. The board of directors is expressly authorized to fix by resolution or resolutions the designations and the powers, preferences and rights, and the qualifications, limitations and restrictions of the shares of each series of Preferred Stock (with respect to each series of Preferred Stock, the "Preferred Stock Designation").

FIFTH. The board of directors of the corporation is expressly authorized to adopt, amend or repeal any bylaws of the corporation by resolutions duly adopted by a majority of the directors then in office (except that prior to the Trigger Date (defined below), the board of directors may not amend or repeal Section 2.10(d) of the Bylaws, or adopt any bylaws inconsistent therewith), but the stockholders entitled to vote may adopt additional bylaws and may amend or repeal any bylaw whether or not adopted by them at a meeting duly called for that purpose by the affirmative vote of the holders of not less than sixty six and two-thirds percent (66 2/3%) of the voting power of all outstanding shares of capital stock of the corporation entitled to vote generally in the election of directors, considered for purposes hereof as a single class. In addition to any other affirmative vote or written consent required by applicable law, this Article FIFTH may not be amended, modified or repealed except with the affirmative vote of holders of not less than sixty six and two-thirds percent (66 2/3%) of the voting power of all outstanding shares of capital stock of the corporation entitled to vote generally on the election of directors, considered for purposes hereof as a single class.

SIXTH. Elections of directors need not be by written ballot except and to the extent provided in the bylaws of the corporation.

SEVENTH. The number of directors of the corporation shall be not less than three (3) nor more than fifteen (15), as may be fixed from time to time by resolutions duly adopted by the board of directors. Effective upon the day following the first day on which the Significant Stockholder(s) (as defined below) and their respective affiliates shall cease to beneficially own, in the aggregate, at least a majority of then issued and outstanding shares of Common Stock (such following day, the "Trigger Date"), the directors of the corporation shall by resolution divide the board into three classes, as nearly equal in number as reasonably possible, as determined by the board of directors, with the initial term of office of the first class of such directors to expire at the first annual meeting of stockholders thereafter, the initial term of office of the second class of such directors to expire at the second annual meeting of stockholders thereafter and the initial term of office of the third class of such directors to expire at the third annual meeting of stockholders thereafter, with each class of directors to hold office until their successors have been duly elected and qualified or until their earlier resignation or removal. At each annual meeting of stockholders following such initial classification and election, directors elected to succeed the directors whose terms expire at such annual meeting shall be elected to hold office for a term expiring at the annual meeting of stockholders in the third year following the year of their election and until their successors have been duly elected and qualified or until their earlier resignation or removal. "Significant Stockholder" means

Merck and any person or entity (i) that is designated by Merck or any other Significant Stockholder as a "Significant Stockholder" for purposes of this Certificate of Incorporation and (ii) to which Merck or such Significant Stockholder, as applicable, sells or otherwise transfers, in any transaction, shares of Common Stock representing at least twenty percent (20%) of the shares of Common Stock issued and outstanding at the time of such transaction.

Prior to the Trigger Date, any director may be removed from office with or without cause by the affirmative vote of the holders of not less than a majority of the voting power of all outstanding shares of capital stock of the corporation entitled to vote generally in the election of directors, considered for purposes hereof as a single class. Effective upon and commencing as of the Trigger Date, a director may only be removed from office for cause and by the affirmative vote of the holders of not less than sixty six and two-thirds percent (66 2/3%) of the voting power of all outstanding shares of capital stock of the corporation entitled to vote generally in the election of directors, considered for purposes hereof as a single class. Any vacancy occurring on the board of directors and any newly created directorship may only be filled by a majority of the remaining directors or by the sole remaining director in office. In the event of the death, resignation, retirement, removal or disqualification of a director during his or her elected term of office, his or her successor shall serve until the next stockholders' meeting at which directors of such class are elected, and until his or her successor is elected and qualified or until his or her earlier resignation or removal. In addition to any other affirmative vote or written consent required by applicable law, this Article SEVENTH may not be amended, modified or repealed except by the affirmative vote of the holders of not less than sixty six and two-thirds percent (66 2/3%) of the voting power of all outstanding shares of capital stock of the corporation entitled to vote generally in the election of directors, considered for purposes hereof as a single class.

**EIGHTH.** Effective upon and commencing as of the Trigger Date and except as otherwise provided pursuant to provisions of the certificate of incorporation of the corporation (including any Preferred Stock Designation) fixing the powers, privileges or rights of any class or series of stock other than the Common Stock in respect of action by written consent of the holders of such class or series of stock, any action required or permitted to be taken by the stockholders of the corporation must be effected at a duly called annual or special meeting of such holders and may not be effected by any consent in writing by such holders.

Until the Trigger Date, the corporation shall be required to call a special meeting of stockholders promptly upon receipt by the corporation of a written request for a special meeting from stockholders holding at least a majority of the voting power of the outstanding shares of capital stock of the corporation entitled to vote generally in the election of directors considered for purposes here as a single class. Any special meeting so requested shall be held on the date, at the time and for the purpose or purposes, set forth in the request therefor. Until the Trigger Date, special meetings of stockholders of the corporation may also be called by the Chairman, President or a majority of the board of directors pursuant to a resolution or resolutions stating the purpose or purposes thereof. Effective upon and commencing as of the Trigger Date, except as otherwise provided pursuant to provisions of the certificate of incorporation of the corporation (including any Preferred Stock Designation) fixing the powers, privileges or rights of any class or series of stock other than the Common Stock, special meetings of stockholders of the corporation of any class or series of capital stock for any purpose or purposes may be called only

by the Chairman, President or a majority of the board of directors pursuant to a resolution stating the purpose or purposes thereof and, effective upon and commencing as of the Trigger Date, any power of stockholders to call a special meeting is specifically denied, and no business other than that stated in the notice shall be transacted at any special meeting.

In addition to any other affirmative vote or written consent required by applicable law, this Article EIGHTH may not be amended, modified or repealed except by the affirmative vote of the holders of not less than sixty six and two-thirds percent (66 2/3%) of the voting power of all outstanding shares of capital stock of the corporation entitled to vote generally in the election of directors, considered for purposes hereof as a single class.

**NINTH.** A director of the corporation shall not be liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except to the extent that such exemption from liability or limitation thereof is not permitted under the DGCL as currently in effect or as the same may hereafter be amended. No amendment, modification or repeal of this Article NINTH shall adversely affect any right or protection of a director with respect to events occurring prior to such amendment, modification or repeal.

**TENTH.** Certain Transactions With Stockholders and Corporate Opportunities.

a) Certain Acknowledgments; Certain Fiduciary Duties.

In anticipation (i) that the corporation will cease to be a wholly owned subsidiary of Merck, but that Merck will remain a stockholder of the corporation and have continued contractual, corporate and business relations with the corporation, and in anticipation that the corporation or its Affiliated Companies (as defined below in this Article TENTH) and Merck or its Affiliated Companies may enter into contracts and/or otherwise transact business with each other and that the corporation may derive benefits therefrom, (ii) that directors, officers and/or employees of Merck and/or of its Affiliated Companies may serve as directors and/or officers of the corporation, (iii) that Merck and/or its Affiliated Companies may engage in the same, similar or related lines of business as those in which the corporation or its Affiliated Companies, directly or indirectly, may engage or other business activities in each case that may overlap with or compete with those in which the corporation or its Affiliated Companies, directly or indirectly, may engage, and that Merck or its Affiliated Companies may compete with the corporation or its Affiliated Companies in any of such business lines and/or business activities and with respect to business opportunities relating to any such business lines and/or business activities, (iv) that the corporation or its Affiliated Companies may from time to time enter into or engage in contractual, business or other relationships with Merck or its Affiliated Companies, and (v) that, as a consequence of the foregoing, it is in the best interests of the corporation that the respective rights and duties of the corporation and of Merck and its Affiliated Companies, and the duties of the directors or officers of the corporation who are also directors, officers or employees of Merck or its Affiliated Companies, be determined and delineated in respect of any transactions between, or opportunities that may be suitable for, both the corporation or its Affiliated Companies, on the one hand, and Merck or its Affiliated Companies, on the other hand, the provisions of this Article TENTH shall regulate and define the conduct of certain of the business and affairs of the corporation in relation to Merck and its Affiliated Companies. Any contractual, business or

other relationship that does not comply with the procedures set forth in this Article TENTH, shall not by reason thereof be deemed void or voidable or unfair or result in any breach of fiduciary duty or duty of loyalty or failure to act in good faith or in the best interests of the corporation or constitute derivation of any improper personal benefit, but shall be governed by the provisions of this certificate of incorporation, the bylaws of the corporation, the DGCL and other applicable law.

#### Certain Agreements and Transactions Permitted.

No contract, agreement, arrangement or transaction (or any amendment, modification or termination thereof) between the corporation or any of its Affiliated Companies, on the one hand, and Merck or any of its Affiliated Companies, on the other hand, or between the corporation or any of its Affiliated Companies, on the one hand, and one or more of the directors or officers of the corporation who are also directors, officers or employees of Merck or any of its Affiliated Companies, on the other hand, or between the corporation and any of its Affiliated Companies shall be void or voidable or be considered to be unfair to the corporation solely for the reason that Merck, any such Affiliated Company, or any one or more of the officers or directors of the corporation, Merck, or any such Affiliated Companies are parties thereto, or because any such directors or officers are present at or participate in any meeting of the board of directors or committee thereof which authorizes the contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof), or because his, her or their votes are counted for such purpose. Further, no such contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof), or the performance thereof by the corporation or any of its Affiliated Companies or by Merck or any of its Affiliated Companies, shall be considered to be for any of the foregoing reasons contrary to (x) any fiduciary duty that Merck or any of its Affiliated Companies may owe to the corporation or to any stockholder of the corporation by reason of Merck or any of its Affiliated Companies being a controlling stockholder of the corporation or participating in the control of the corporation or of any of its Affiliated Companies; or (y) any fiduciary duty owed to the corporation or to any stockholder of the corporation by any director or officer of the corporation or of any of its Affiliated Companies who is also a director, officer or employee of Merck or any of its Affiliated Companies; and Merck, any of its Affiliated Companies, and such directors and officers of the corporation or any of its Affiliated Companies shall be deemed to have acted in good faith and in a manner such persons reasonably believe to be in and not opposed to the best interests of the corporation and shall be deemed not to have breached their duties of loyalty to the corporation or its stockholders, and not to have derived an improper personal benefit therefrom, if any of the following conditions shall have been satisfied:

(i) such contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) shall have been entered into before the corporation ceased to be a wholly owned subsidiary of Merck and continued in effect in respect of any such transaction or opportunity after such time; or

(ii) the material facts as to the contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) are disclosed or are known to the board of directors or the applicable committee thereof which authorizes or ratifies the contract, agreement,

arrangement or transaction (or the amendment, modification or termination thereof), and such contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) is authorized, approved or ratified (a) by the affirmative vote of a majority of the members (even though less than a quorum) who are not Interested Persons (as hereinafter defined) in respect of such contract, agreement, arrangement, transaction, amendment, modification or termination; (b) by the affirmative vote of a majority of the members of a committee constituted solely of members who are not Interested Persons in respect of such contract, agreement, arrangement, transaction, amendment, modification or termination or (c) by one or more officers or employees of the corporation (including officers or employees of the corporation acting as directors, officers, trustees, partners or members of, or in any similar capacity on behalf of, any Affiliated Company of the corporation) who in each case is not an Interested Person in respect of such contract, agreement, arrangement, transaction, amendment, modification or termination and to whom the authority to approve or ratify such contract, agreement, arrangement, transaction, amendment, modification or termination has been delegated either by the board of directors by the same affirmative vote required by subclause (a) of this subparagraph for authorization, approval or ratification of such contract, agreement, arrangement, transaction, amendment, modification or termination by the board of directors or by a committee of the board of directors constituted as provided by and acting by the same affirmative vote as required by subclause (b) of this subparagraph for authorization, approval or ratification of such contract, agreement, arrangement, transaction, amendment, modification or termination by such committee or, in the case of an employee, to whom such authority has been delegated by an officer to whom authority to approve such contract, agreement, arrangement, transaction, amendment, modification or termination has been so delegated; provided, however, that, before such authorization or approval or ratification, the material facts of the relationship between the corporation or such Affiliated Company thereof, on the one hand, and Merck or such Affiliated Company thereof, on the other hand, and the material facts as to such contract, agreement, transaction, amendment, modification or termination, as the case may be, were disclosed to or were known by the members of the board of directors or of such committee or the officer or officers or employee or employees who acted with respect to the authorization, approval or ratification of such contract, agreement, transaction, amendment, modification or termination, as the case may be; or

(iii) the material facts as to the contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) are disclosed to or are known by the holders of capital stock of the corporation entitled to vote thereon, and the contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) is approved or ratified by vote of the holders of a majority of the shares of capital stock of the corporation (not owned by Merck or an Affiliated Company or any Interested Persons in respect of such transaction) entitled to vote thereon and who do vote thereon; or

(iv) such contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) is fair as to the corporation as of the time it is entered into by the corporation or any Affiliated Company thereof or authorized, approved or ratified by the board of directors, a committee thereof or the stockholders of the corporation.

Neither Merck nor any of its Affiliated Companies, as a stockholder of the corporation or participant in control of the corporation, shall have or be under any fiduciary duty to refrain from entering into any contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) or to refrain from participating in any transaction that meets the requirements of any of clauses (i), (ii), (iii) or (iv), of the immediately preceding sentence and no director, officer or employee of the corporation or any of its Affiliated Companies who is also a director, officer or employee of Merck or any of its Affiliated Companies shall have or be under any fiduciary duty to the corporation to refrain from acting on behalf of the corporation or any of its Affiliated Companies in respect of any such contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) or to refrain from performing any such contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) in accordance with its terms. Directors of the corporation who are also directors or officers of Merck or any of its Affiliated Companies may be counted in determining the presence of a quorum at a meeting of the board of directors or of a committee which authorizes, approves or ratifies the contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof). Shares of capital stock of the corporation owned by Merck or any of its Affiliated Companies may be counted in determining the presence of a quorum at a meeting of stockholders which approves or ratifies the contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof). Any person purchasing or otherwise acquiring any shares of capital stock of the corporation, or any interest therein, shall be deemed to have notice of and to have consented to the provisions of this Article TENTH. The failure of any contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) between the corporation or any of its Affiliated Companies, on the one hand, and Merck or any of its Affiliated Companies, on the other hand, to satisfy the requirements of this Article TENTH shall not, by itself, cause such contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) to constitute any breach of any fiduciary duty to the corporation or to any of its Affiliated Companies, or to any stockholder or other owner of an equity interest therein, by any controlling stockholder of the corporation or such Affiliated Company thereof or by any director, officer or employee of the corporation.

#### Certain Corporate Opportunities.

Merck and its Affiliated Companies shall have no duty to refrain from engaging in the same or similar activities or lines of business as the corporation or its Affiliated Companies, and except as provided below, neither Merck, its Affiliated Companies nor any officer, director or employee of Merck or any of its Affiliated Companies shall be liable to the corporation or stockholders of the corporation for breach of any fiduciary duty by reason of any such activities of Merck or its Affiliated Companies or of such person. In the event that Merck or any of its Affiliated Companies acquires knowledge of a potential transaction or matter which may be a corporate opportunity for both Merck or any of its Affiliated Companies and the corporation or any of its Affiliated Companies, neither Merck nor any of its Affiliated Companies shall have any duty to communicate or offer such corporate opportunity to the corporation or any of its Affiliated Companies and neither Merck nor any of its Affiliated Companies shall be liable to the corporation or to the stockholders of the corporation for breach of any fiduciary duty as a stockholder of the corporation by reason of the fact that Merck or any of its Affiliated

Companies pursues or acquires such corporate opportunity for itself, directs such corporate opportunity to another person (including to Merck or one or more of Merck's Affiliated Companies), or does not communicate information regarding such corporate opportunity to the corporation.

In the event that a director or officer of the corporation or one or more of its Affiliated Companies, who is also a director or officer of Merck or one or more of its Affiliated Companies, acquires knowledge of a potential transaction or matter which may be a corporate opportunity for both the corporation or one or more of its Affiliated Companies and Merck or one or more of its Affiliated Companies, such director or officer shall have fully satisfied and fulfilled his or her fiduciary duty to the corporation and to the stockholders of the corporation with respect to such corporate opportunity, and shall not be liable to the corporation or the stockholders of the corporation for breach of any fiduciary duty by reason of the fact that Merck or any of its Affiliated Companies pursues or acquires such corporate opportunity for itself or directs such corporate opportunity to another person (including to Merck or one or more of its Affiliated Companies) or does not communicate information regarding such corporate opportunity to the corporation, if such director or officer acts consistent with the following: a corporate opportunity offered to any person who is a director or officer of the corporation or one or more of its Affiliated Companies, and who is also a director or officer of Merck or one or more of its Affiliated Companies, shall belong to the corporation or its Affiliated Companies only if such opportunity is expressly offered to such person solely in his or her capacity as a director or officer of the corporation or one or more of its Affiliated Companies, and if such opportunity is not expressly offered to such person solely in such capacity, the opportunity shall belong solely to Merck or one or more of its Affiliated Companies.

#### Certain Definitions.

For purposes of this Article TENTH, the following definitions shall apply:

"Affiliated Company" shall mean in respect of Merck, any company which is controlled by Merck, controls Merck or is under common control with Merck (other than the corporation and any company that is controlled by the corporation), and in respect of the corporation shall mean any company controlled by the corporation.

"Interested Person" in respect of an agreement or transaction referred to in this Article TENTH shall mean any director, officer or employee of Merck or any of its Affiliated Companies and any person who has a financial interest that is material to such person in Merck or such Affiliated Company or otherwise has a personal financial interest that is material to such person in such agreement or transaction; provided, however, that no such financial interest shall be considered material by reason of a person's ownership of securities of Merck or any of its Affiliated Companies, if such ownership of securities has been determined in good faith not to be reasonably likely to influence such individual's decision on behalf of the corporation or any of its Affiliated Companies in respect of the contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) either in the specific instance by, or pursuant to a policy adopted by, the board of directors of the corporation by the affirmative vote of a majority of the members (even though less than a quorum) who are not directors, officers or

employees of Merck or any of its Affiliated Companies or a committee of the board of directors of the corporation constituted solely of members who are not directors, officers or employees of Merck or any of its Affiliated Companies by the affirmative vote of a majority of such committee.

The provisions of this Article TENTH shall have no further force or effect as to Merck at such time as Merck and its Affiliated Companies shall first cease to own, in the aggregate, shares of capital stock representing at least twenty percent (20%) or more of the votes entitled to be cast by the holders of all the then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors; provided, however, that such termination shall not terminate the effect of such provisions with respect to (i) any contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof) between the corporation or any of its Affiliated Companies and Merck or any of its Affiliated Companies that was entered into before such time or any transaction entered into in the performance of any such contract, agreement, arrangement or transaction (or the amendment, modification or termination thereof), whether entered into before or after such time, or (ii) any transaction between the corporation or any of its Affiliated Companies and Merck or any of its Affiliated Companies that was entered into before such time or (iii) the allocation of any opportunity between the corporation or any of its Affiliated Companies and Merck or any of its Affiliated Companies that first arose before such time.

The provisions of this Article TENTH applicable to Merck (including the provision contained in this paragraph) shall apply to any Significant Stockholder (as if such entity were Merck).

In addition to any other affirmative vote or written consent required by applicable law, this Article TENTH may not be amended, modified or repealed except by the affirmative vote of the holders of not less than eighty percent (80%) of the voting power of all outstanding shares of stock of the corporation entitled to vote generally in the election of directors, considered for purposes hereof as a single class.

**ELEVENTH.** Section 203 of the Delaware General Corporation Law.

Until the Trigger Date, the corporation shall not be governed by Section 203 of the Delaware General Corporation Law, as amended, or any successor statute ("Section 203"). Effective upon and commencing as of the Trigger Date, the corporation shall be governed by Section 203; provided that Section 203 shall not apply to any "business combination" with any "interested stockholder" (both as defined in Section 203) who was an "interested stockholder" prior to the Trigger Date and who remains an "interested stockholder" thereafter at all times through the consummation of such business combination.

In addition to any other affirmative vote or written consent required by applicable law, this Article ELEVENTH may not be amended, modified or repealed except by the affirmative vote of the holders of not less than sixty six and two-thirds percent (66 2/3%) of the voting power of all outstanding shares of stock of the corporation entitled to vote generally in the election of directors, considered for purposes hereof as a single class.



IN WITNESS WHEREOF, MedcoHealth Solutions, Inc. has caused this Amended and Restated Certificate of Incorporation to be duly executed by an authorized officer of MedcoHealth Solutions, Inc. as of this 6th day of June , 2002.

MEDCOHEALTH SOLUTIONS, INC.

By: /s/ David S. Machlowitz

Name: David S. Machlowitz

Title: Senior Vice President, General Counsel  
and Secretary